Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
Article in Annals of Hematology (December 2023)
The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.
Assessment of Time-to-onset and Outcome of Lung Adverse Events With Pomalidomide from a Pharmacovigilance Study
Article in In Vivo (March 2023)
Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment
Article in International Journal of Hematology (April 2022)